Tower Research Capital (TRC)’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-10,603
| Closed | -$2K | – | 6874 |
|
|
2022
Q3 | $2K | Sell |
10,603
-14,600
| -58% | -$2.75K | ﹤0.01% | 5714 |
|
|
2022
Q2 | $15K | Buy |
25,203
+24,950
| +9,862% | +$14.8K | ﹤0.01% | 4117 |
|
|
2022
Q1 | $0 | Buy |
253
+143
| +130% | – | ﹤0.01% | 7029 |
|
|
2021
Q4 | $0 | Sell |
110
-8,012
| -99% | – | ﹤0.01% | 6917 |
|
|
2021
Q3 | $26K | Buy |
8,122
+4,557
| +128% | +$14.6K | ﹤0.01% | 3504 |
|
|
2021
Q2 | $13K | Sell |
3,565
-131
| -4% | -$478 | ﹤0.01% | 4258 |
|
|
2021
Q1 | $13K | Sell |
3,696
-6,190
| -63% | -$21.8K | ﹤0.01% | 4233 |
|
|
2020
Q4 | $33K | Sell |
9,886
-6,779
| -41% | -$22.6K | ﹤0.01% | 3502 |
|
|
2020
Q3 | $58K | Buy |
16,665
+13,605
| +445% | +$47.4K | ﹤0.01% | 3479 |
|
|
2020
Q2 | $14K | Buy |
3,060
+2,236
| +271% | +$10.2K | ﹤0.01% | 3885 |
|
|
2020
Q1 | $3K | Buy |
824
+451
| +121% | +$1.64K | ﹤0.01% | 2517 |
|
|
2019
Q4 | $2K | Sell |
373
-1,329
| -78% | -$7.13K | ﹤0.01% | 3156 |
|
|
2019
Q3 | $7K | Buy |
1,702
+1,276
| +300% | +$5.25K | ﹤0.01% | 3174 |
|
|
2019
Q2 | $6K | Buy |
+426
| New | +$6K | ﹤0.01% | 2893 |
|
|
2019
Q1 | – | Sell |
-408
| Closed | -$1K | – | 4492 |
|
|
2018
Q4 | $1K | Buy |
+408
| New | +$1K | ﹤0.01% | 3704 |
|